Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) Research & Development (2021 - 2026)

bioAffinity Technologies has reported Research & Development over the past 5 years, most recently at $349707.0 for Q1 2026.

  • Quarterly Research & Development fell 4.81% to $349707.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Mar 2026, down 4.83% year-over-year, with the annual reading at $1.4 million for FY2025, 5.33% down from the prior year.
  • Research & Development was $349707.0 for Q1 2026 at bioAffinity Technologies, down from $374012.0 in the prior quarter.
  • Over five years, Research & Development peaked at $450612.0 in Q4 2022 and troughed at $248419.0 in Q2 2022.
  • The 5-year median for Research & Development is $349707.0 (2026), against an average of $350638.4.
  • Year-over-year, Research & Development soared 34.9% in 2023 and then dropped 22.63% in 2025.
  • A 5-year view of Research & Development shows it stood at $450612.0 in 2022, then decreased by 3.95% to $432818.0 in 2023, then fell by 9.74% to $390658.0 in 2024, then decreased by 4.26% to $374012.0 in 2025, then decreased by 6.5% to $349707.0 in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Research & Development are $349707.0 (Q1 2026), $374012.0 (Q4 2025), and $330589.0 (Q3 2025).